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Case 1: 
• 10 year old, ongoing study of Hirschsprung Disease 
• Family history, Medical questionnaire, and DNA samples 
• 5 years ago, new evidence showed Hirschsprung Disease 
associated with second mutation RET gene, which causes 
a highly penetrant, dominant, adult-onset thyroid cancer. 
• No therapy, but prophylactic thyroidectomy often recommended 
• Your study starts screening participant DNA for RET 
mutation as well. 
• You find two participants with RET mutation, one a minor 
(one year old girl) and another a 35-year old man.   
• What are the considerations? 
• What are your options? 




• Jane is 33 years old, accountant, mother of two. 
• Presented to doctor with breast mass and no family history 
• Tests show metastasized cancer  
• She was in a study at age 14 for Hodgkin’s disease and 
received experimental radiation therapy. 
• Long-term follow-up showed 30-fold increase in breast 
carcinoma for those who received experimental radiation 
therapy and suggests regular mammography for women 8-10 
years after this treatment. 
• Jane didn’t know this and is very upset. 
• What could/should have been done? 
• What could/should be done now?  
Difference between two cases? 
• Individual vs. aggregate results 
• Actionable vs. unactionable results 
• Adult vs. minor 
• Reliability of results 
• Feasibility of action 
• Others? 
Research results are “public”.  How? 
• Published in journals 
• Clinicaltrials.gov 
• Academic conferences 
• CME to health professionals 
• Lay media (sometimes) 
But what about the actual participants? 
Why? [Ethically speaking] 
• Respect for persons 
• Beneficence 
• Justice 
Respect for persons 
• Most people want it 
• Review of studies by Shalowitz and Miller (2008) found a median of 
90% of people wanted either individual or aggregate results (more 
than half were involved in cancer or genetic studies) 
Beneficence 
• Individual 
• “You may get better, stay the same, or get worse from being in this 
study.” 
• “You have little to no chance of benefit from being in this study.” 
 
• Society 
• Generalizable knowledge 
• Future medical advances 
Beneficence of returning results 
• Objective criteria usually used 
• Analytic validity 
• Clinical validity 
• Clinical utility 
• But also, subjectively helpful  
• Behavior change 
• Life planning 
• Reproductive planning 
• Etc. 
 
Is there a third type of benefit? 
• Disseminating aggregate results to participant community. 
• What good could this do? 
• Health benefits (like Jane) 
• Feelings of self-worth 
• Comfort from loss (family of lost Phase I oncology participants) 
• Avoid anger at learning results from media as opposed to medical 
providers (Goodare 1995, Rich 1999) 
Other benefits (besides ethics)? 
• Facilitating communication between clinicians and 
patients 
• Increase satisfaction with study participation  more 
study participation 





• Lack of expertise (participants misunderstand and misuse 
information) 
• Causing distress (if study didn’t yield positive results, or 
found out afterwards in an inferior treatment group) 
• Compromising future follow-ups 
 




• At time active participation ends 
• At time of publication 
 
• Best option: Time of publication 
• Least likely to lead to confusion or misunderstanding 
• Least economically and administratively burdensome 




• Given by research team, face-to-face 
• Given by clinicians, face-to-face 
• Group meeting 
• Mailed 
• Emailed 
• Letter notifying results are available, directed to call if they want 
results 
• Letter notifying results are available, given link to web address 
• Others? 
• Best option 




Some lessons. . . 
• Incorporate plan into trial design  
• Being directed to web or telephone solves the problem of 
consent 
• Internet, although not always preferred by patients, has 
been shown to increase uptake 
• Negative aggregate results have been well-received as 
well as positive 
• Negative individual results should be given in person 
• Information about inferior treatments should be given in 
person 
• Just before or simultaneous with media 
 
Cases revisited. . . 
• What should we do about Hirschsprung Disease study? 
• What should we do about Jane? 
Thank you. 
 
